RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.About us
We are interested in cooperation with the authors of new promising ideas in the field of pharmaceuticals and medical equipment.Portfolio
Rusnano and Domain have made an agreement on joint investments in pharmaceuticals and medical development for innovation.About agreement
RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.Our history
RMI was created in March 2012.
Initial funding - $380 million.
The RusnanoMedInvest fund was established by RUSNANO, the nanotechnology investment, research and development arm of the Russian Government together with Domain Associates LLC, one of the premier U.S. life sciences technology venture investment firms. The RusnanoMedInvest fund seeks, in addition to securing differentiated and sustainable returns to its investment portfolio, to promote the following social and developmental objectives in Russia
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region.
29 July 2016
29 July 2016